Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Faculty of Tropical Medicine (FTM), Mahidol University, Thailand hosted a Congratulations party to honour Professor Sir Nicholas J. White, FRS, OBE on the occasion of his receiving Knight Commander of the Order of St. Michael and St. George from the United Kingdom for services to Tropical Medicine and Global Health.

Nick White and his group

On 14th February, the Faculty of Tropical Medicine (FTM), Mahidol University, Thailand hosted a Congratulations party to honour Professor Sir Nicholas J. White, FRS, OBE on the occasion of his receiving Knight Commander of the Order of St. Michael and St. George from the United Kingdom for services to Tropical Medicine and Global Health.

A Professor of Tropical Medicine at the University of Oxford (UK) and Mahidol University, a Fellow of St John's College and Chairman of the Wellcome Trust's South East Asian Research Units, Professor White's research interests include the pathophysiology and treatment of severe malaria, the prevention of antimalarial drug resistance using artemisinin-based combinations, and the biology of relapse in vivax malaria. He has lived and worked in Thailand for over 30 years.

After congratulatory speeches from FTM Dean Pratap Singhasivanon and MORU Director Professor Nicholas PJ Day, Professor White received a flower bouquet and souvenir from Dean Pratap. Held in the FTM’s Rajanakarindra Building, the event was well attended by Professor Sir Nick’s colleagues and members of the Faculty.

Similar stories

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU OCGHR Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments OCGHR

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU OCGHR

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU OCGHR Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.